<?xml version="1.0" encoding="iso-8859-1"?>
<rss version="2.0">
	<channel>
	<link>http://salesandmarketingnetwork.com/hsmn_newsfeed_public.rss</link>
	<title>HSMN NewsFeed</title>
	<description><![CDATA[Healthcare Sales & Marketing Network NewsFeed]]></description>
	<lastBuildDate>Tue, 09 Feb 2010 07:54:31 CST</lastBuildDate>
	<language>en-us</language>
	<image>
	<title><![CDATA[The Healthcare Sales & Marketing Network]]></title>
	<width>150</width>
	<height>67</height>
	<link>http://salesandmarketingnetwork.com/news.php</link>
	<url>http://salesandmarketingnetwork.com/images/hsmn_logo_150.gif</url>
	</image>
	<item>
		 <title><![CDATA[Debiopharm Group Grants an Exclusive Licence for the Development, Manufacture and Commercialisation of Debio 025]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030064</link>
			<pubDate>Tue, 09 Feb 2010 12:52:14 GMT</pubDate>
			<author><![CDATA[Debiopharm]]></author>
		 <description><![CDATA[A Potent, First-in-class Antiviral Agent for the Treatment of Hepatitis C

LAUSANNE, Switzerland, February 9  (HSMN NewsFeed)  -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of ... <br/><font color="red">Biopharmaceuticals, Licensing</font><br/><font color="blue">Debiopharm, Novartis, Debio 025, alisporivir, hepatitis C</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Denosumab Demonstrated Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Prostate Cancer Patients With Bone Metastases]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030063</link>
			<pubDate>Tue, 09 Feb 2010 01:10:30 GMT</pubDate>
			<author><![CDATA[Amgen]]></author>
		 <description><![CDATA[Denosumab Trial Met Primary and All Secondary Endpoints by Significantly Delaying Time to First Skeletal Related Event and Significantly Reducing First-and-Subsequent Skeletal Related Events Compared to Zometa 
Second Phase 3 Advanced Cancer Trial to Demo... <br/><font color="red">Biopharmaceuticals, Oncology</font><br/><font color="blue">Amgen, denosumab, Zometa, zoledronic, bone metastases</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Lupin Receives FDA Approval for Amlodipine/Benazepril Capsules]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030062</link>
			<pubDate>Mon, 08 Feb 2010 20:40:18 GMT</pubDate>
			<author><![CDATA[Lupin Pharmaceuticals]]></author>
		 <description><![CDATA[BALTIMORE, Feb. 8  (HSMN NewsFeed)  -- Lupin Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (U.S. FDA) has granted final approval for its Amlodipine/Benazepril 2.5mg/10mg, 5mg/10mg, 5mg/20mg and 10mg/20mg capsules.  Commer... <br/><font color="red">Biopharmaceuticals, FDA, Generics</font><br/><font color="blue">Lupin Pharmaceuticals, Amlodipine, Benazepril, Novartis, Lotrel</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Sagent Pharmaceuticals Announces FDA Approval of Labetalol Hydrochloride Injection, USP]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030061</link>
			<pubDate>Mon, 08 Feb 2010 20:30:55 GMT</pubDate>
			<author><![CDATA[Sagent Pharmaceuticals]]></author>
		 <description><![CDATA[SCHAUMBURG, Ill., Feb. 8  (HSMN NewsFeed)  -- Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced that it has received FDA approval of labetalol hydrochloride (HCl) injection, USP, commonly used to control sever... <br/><font color="red">Biopharmaceuticals, Generics, Cardiology, FDA</font><br/><font color="blue">Sagent Pharmaceuticals, labetalol, Prometheus Laboratories, Trandate</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Banyan Biomarkers Announces New Chief Executive Officer]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030060</link>
			<pubDate>Mon, 08 Feb 2010 20:14:16 GMT</pubDate>
			<author><![CDATA[Banyan Biomarkers]]></author>
		 <description><![CDATA[ALACHUA, Fla.--(HSMN NewsFeed)--Banyan Biomarkers, Inc., the leader in developing in vitro diagnostic products to address unmet clinical needs for the detection of traumatic brain injury, announced today the appointment of Jackson Streeter, M.D. as Chief E... <br/><font color="red">Diagnostics, Neurology, Personnel</font><br/><font color="blue">Banyan Biomarkers, traumatic brain injury</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[KineMed Broadens Collaboration with Bristol-Myers Squibb]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030059</link>
			<pubDate>Mon, 08 Feb 2010 20:11:20 GMT</pubDate>
			<author><![CDATA[KineMed]]></author>
		 <description><![CDATA[EMERYVILLE, Calif.--(HSMN NewsFeed)--KineMed, Inc. a translational and personalized medicine development company, today announced a broadening of its collaboration with Bristol-Myers Squibb Company (NYSE: BMY ) in the area of Alzheimer’s disease and other ... <br/><font color="red">Biopharmaceuticals, Personalized Medicine, Neurology</font><br/><font color="blue">KineMed, Bristol-Myers Squibb, Alzheimer’s disease</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Abbott Submits New Automated Ovarian Cancer Test for U.S. Approval]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030058</link>
			<pubDate>Mon, 08 Feb 2010 20:08:55 GMT</pubDate>
			<author><![CDATA[Abbott]]></author>
		 <description><![CDATA[Abbott's ARCHITECT human epididymis protein 4 (HE4) assay submitted for 510(k) clearance

ABBOTT PARK, Ill., Feb. 8  (HSMN NewsFeed)  -- A new diagnostic tool physicians can use to monitor patients for the most common form of ovarian cancer may soon be a... <br/><font color="red">Diagnostics, Oncology, FDA</font><br/><font color="blue">Abbott, ARCHITECT HE4, HE4, ovarian cancer</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Aton Pharma Announces Michael H. Richardson to Head Orphan Drug Division]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030057</link>
			<pubDate>Mon, 08 Feb 2010 18:58:04 GMT</pubDate>
			<author><![CDATA[Aton Pharma]]></author>
		 <description><![CDATA[LAWRENCEVILLE, N.J., Feb. 8  (HSMN NewsFeed)  -- Aton Pharma, Inc., a diversified specialty pharmaceutical company, announced today that Michael H. Richardson has joined the company as Vice President, Commercial Operations for the newly formed Orphan Drug ... <br/><font color="red">Biopharmaceuticals, Personnel</font><br/><font color="blue">Aton Pharma, Orphan Drug</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[BD Announces Worldwide Voluntary Recall of BD Q-Syte(TM) Luer Access Devices and BD Nexiva(TM) Closed IV Catheter Systems]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030056</link>
			<pubDate>Mon, 08 Feb 2010 13:46:49 GMT</pubDate>
			<author><![CDATA[Becton, Dickinson]]></author>
		 <description><![CDATA[FRANKLIN LAKES, N.J., Feb. 8  (HSMN NewsFeed)  -- BD (Becton, Dickinson and Company) (NYSE: BDX) has voluntarily executed a product recall of certain lots of BD Q-Syte Luer Access Devices and BD Nexiva Closed IV Catheter Systems.  Use of the affected devic... <br/><font color="red">Devices, Product Recall</font><br/><font color="blue"> BD , Becton Dickinson, Q-Syte Luer Access, Nexiva Closed IV</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Neuraltus Pharmaceuticals Names Andrew Gengos President and CEO]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030055</link>
			<pubDate>Mon, 08 Feb 2010 13:39:57 GMT</pubDate>
			<author><![CDATA[Neuraltus Pharmaceuticals]]></author>
		 <description><![CDATA[PALO ALTO, CA, Feb 8 --(HSMN NewsFeed)-- Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing products that address critical unmet needs primarily in the treatment of neurodegenerative diseases, ... <br/><font color="red">Biopharmaceuticals, Personnel</font><br/><font color="blue">Neuraltus Pharmaceuticals</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Synovis Life Technologies Receives FDA Marketing Clearance for Flow Coupler(R)]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030054</link>
			<pubDate>Mon, 08 Feb 2010 13:37:13 GMT</pubDate>
			<author><![CDATA[Synovis Life Technologies]]></author>
		 <description><![CDATA[Microsurgical Device Assesses Blood Flow After Connecting Small Blood Vessels

ST. PAUL, Minn.--(HSMN NewsFeed)--Synovis Life Technologies, Inc. (Nasdaq: SYNO ), has received Food and Drug Administration 510(k) marketing clearance for its Flow Coupler&re... <br/><font color="red">Devices, Surgery, FDA</font><br/><font color="blue">Synovis Life Technologies, Flow Coupler, Microvascular Anastomotic Coupler</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030053</link>
			<pubDate>Mon, 08 Feb 2010 13:33:21 GMT</pubDate>
			<author><![CDATA[Anthera Pharmaceuticals]]></author>
		 <description><![CDATA[HAYWARD, Calif., Feb. 8  (HSMN NewsFeed)  -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, announced today that it reached an agreement with the U.S. Food ... <br/><font color="red">Biopharmaceuticals, Cardiology, Personnel</font><br/><font color="blue">Anthera Pharmaceuticals, VISTA-16, Varespladib</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Stereotaxis Installs First System in Taiwan]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030052</link>
			<pubDate>Mon, 08 Feb 2010 13:28:06 GMT</pubDate>
			<author><![CDATA[Stereotaxis]]></author>
		 <description><![CDATA[Expands presence in Asia Pacific to 12 systems

ST. LOUIS, Feb. 8  (HSMN NewsFeed)  -- Stereotaxis (Nasdaq: STXS) today announced the installation of its first Stereotaxis Magnetic Navigation System in Taiwan at Cheng-Hsin General Hospital (CHMC) located... <br/><font color="red">Devices, Cardiology</font><br/><font color="blue">Stereotaxis, Magnetic Navigation System</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Novus Scientific Receives FDA Clearance for TIGR(TM) Matrix Surgical Mesh - World's 1st Long-Term Resorbable Synthetic Mesh]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030051</link>
			<pubDate>Fri, 05 Feb 2010 22:35:22 GMT</pubDate>
			<author><![CDATA[Novus Scientific]]></author>
		 <description><![CDATA[SINGAPORE, UPPSALA, Sweden and CANTON, Mass., Feb. 5  (HSMN NewsFeed)  -- Novus Scientific Pte. Ltd today announced that the US Food and Drug Administration (FDA) has given the company 510(k) clearance to market the TIGR Matrix Surgical Mesh, for use in re... <br/><font color="red">Devices, FDA</font><br/><font color="blue">Novus Scientific, TIGR Matrix, Surgical Mesh</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Study Suggests Slide-On(R) EndoSheath(R) System Provides Several Advantages over Traditional Germicidal Immersion]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030050</link>
			<pubDate>Fri, 05 Feb 2010 14:45:46 GMT</pubDate>
			<author><![CDATA[Medtronic]]></author>
		 <description><![CDATA[Study Presented at the Combined Sections Meetings of the Triological Society, the most prestigious society in Otolaryngology, received the John J. Conley Resident Research Award (Eastern Section)

MINNEAPOLIS--(HSMN NewsFeed)--Results of a clinical study... <br/><font color="red">Devices</font><br/><font color="blue">Medtronic, Slide-On, EndoSheath</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Benefits of CyberKnife Radiosurgery for Lung Cancer Drive Continued Adoption]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030049</link>
			<pubDate>Fri, 05 Feb 2010 13:42:44 GMT</pubDate>
			<author><![CDATA[Accuray]]></author>
		 <description><![CDATA[SUNNYVALE, Calif., Feb. 5  (HSMN NewsFeed)  -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that more than 12,000 courses of lung cancer treatment have been completed with CyberKnife radiosurgery. Usage... <br/><font color="red">Devices, Oncology</font><br/><font color="blue">Accuray, CyberKnife, radiosurgery</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Teva Announces Settlement in Principle regarding Certain Drug Pricing Lawsuits]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030048</link>
			<pubDate>Fri, 05 Feb 2010 13:38:24 GMT</pubDate>
			<author><![CDATA[Teva Pharmaceutical]]></author>
		 <description><![CDATA[JERUSALEM--(HSMN NewsFeed)--Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA ) announced today that several of its subsidiaries in the United States reached a settlement in principle to resolve claims brought by Ven-A-Care of the Florida Keys, Inc. on beh... <br/><font color="red">Biopharmaceuticals, Litigation</font><br/><font color="blue">Teva Pharmaceutical, Ven-A-Care</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Sorin Group Announces Market Release and First Implant of Next-Generation Cardiac Resynchronization Therapy Defibrillator]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030047</link>
			<pubDate>Fri, 05 Feb 2010 13:34:26 GMT</pubDate>
			<author><![CDATA[Sorin Group]]></author>
		 <description><![CDATA[New PARADYM™ CRT Model 8750 is the World’s Highest Output Device Delivering 37J of Energy Quickly and Accurately

MILAN--(HSMN NewsFeed)--Sorin Group  (MIL:SRN) (Reuters Code: SORN.MI), a global leader in the treatment of cardiovascular disease, announce... <br/><font color="red">Devices, Cardiology</font><br/><font color="blue">Sorin Group, CRT-D, Paradym, cardiac resynchronization</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Amicus Therapeutics Board of Directors Names Chief Executive Officer John F. Crowley Chairman of the Board]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030046</link>
			<pubDate>Fri, 05 Feb 2010 13:28:58 GMT</pubDate>
			<author><![CDATA[Amicus Therapeutics]]></author>
		 <description><![CDATA[Donald J. Hayden, Jr. elected Lead Independent Director

CRANBURY, N.J., Feb. 5  (HSMN NewsFeed)  -- Amicus Therapeutics (Nasdaq: FOLD) announced today that its Board of Directors has elected John F. Crowley as Chairman of the Board in addition to his cu... <br/><font color="red">Biopharmaceuticals, Personnel</font><br/><font color="blue">Amicus Therapeutics</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[BioMarin to Acquire LEAD Therapeutics]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030045</link>
			<pubDate>Thu, 04 Feb 2010 22:02:34 GMT</pubDate>
			<author><![CDATA[BioMarin Pharmaceutical]]></author>
		 <description><![CDATA[Key Asset is LT-673, PARP Inhibitor for the Treatment of Genetically Defined Cancers

Conference Call and Webcast to Be Held Today at 5:00 p.m. ET

NOVATO, Calif., Feb. 4  (HSMN NewsFeed)  -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today ... <br/><font color="red">Biopharmaceuticals, Mergers & Acquisitions, Oncology</font><br/><font color="blue">BioMarin Pharmaceutical, LEAD Therapeutics</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Elekta Expands Consultative Services Program to Help MOSAIQ Customers Demonstrate Meaningful Use Guidelines]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030044</link>
			<pubDate>Thu, 04 Feb 2010 21:56:19 GMT</pubDate>
			<author><![CDATA[Elekta]]></author>
		 <description><![CDATA[STRATEGIQ(TM) consultative services offer competitive advantage to U.S. Elekta centers eager to demonstrate HITECH requirements

ATLANTA, Feb. 4  (HSMN NewsFeed)  -- Given the intricacies surrounding the Health Information Technology for Economic and Cli... <br/><font color="red">Devices, Oncology</font><br/><font color="blue">Elekta, STRATEGIQ, HITECH Act</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Bioheart Launches First US FDA Approved Clinical Trial that Tests Gene-Modified Stem Cell Therapy in Patients with Congestive Heart Failure]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030043</link>
			<pubDate>Thu, 04 Feb 2010 21:47:39 GMT</pubDate>
			<author><![CDATA[Bioheart]]></author>
		 <description><![CDATA[SUNRISE, Fla.--(HSMN NewsFeed)--Bioheart, Inc., (OTCBB:BHRT ) announced today that the company has commenced work on its REGEN trial, a Phase I Clinical Trial to test genetically modified MyoCell&reg; in patients suffering from Congestive Heart Failure (CH... <br/><font color="red">Regenerative Medicine, Cardiology</font><br/><font color="blue">Bioheart, MyoCell, REGEN trial, stem cell</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[ADVENTRX Announces Management Promotions]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030042</link>
			<pubDate>Thu, 04 Feb 2010 13:47:37 GMT</pubDate>
			<author><![CDATA[ADVENTRX Pharmaceuticals]]></author>
		 <description><![CDATA[SAN DIEGO, Feb. 4  (HSMN NewsFeed)  -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that, effective immediately, Brian M. Culley, previously the Company's Chief Business Officer and a Senior Vice President, will serve as its Chief Execut... <br/><font color="red">Biopharmaceuticals, Personnel</font><br/><font color="blue">ADVENTRX Pharmaceuticals</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[NeurogesX Announces Management Team Promotions]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030041</link>
			<pubDate>Thu, 04 Feb 2010 13:45:12 GMT</pubDate>
			<author><![CDATA[NeurogesX]]></author>
		 <description><![CDATA[MATEO, Calif., Feb. 4  (HSMN NewsFeed)  -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that three management team members have received promotions:
... <br/><font color="red">Biopharmaceuticals, Personnel</font><br/><font color="blue">NeurogesX</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[St. Jude Medical Announces European Approval of Smaller, Higher Power ICD and CRT-D Devices with New Heart Failure Monitors]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030040</link>
			<pubDate>Thu, 04 Feb 2010 13:41:36 GMT</pubDate>
			<author><![CDATA[St. Jude Medical]]></author>
		 <description><![CDATA[New products help ensure effective therapy delivery even for patients with high defibrillation thresholds, provide additional disease management monitors for heart failure patients or patients at risk for sudden cardiac arrest and can be implanted through ... <br/><font color="red">Devices, Cardiology</font><br/><font color="blue">St. Jude Medical, Fortify ST, ICD , CRT-D</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030039</link>
			<pubDate>Thu, 04 Feb 2010 13:37:56 GMT</pubDate>
			<author><![CDATA[Chimerix]]></author>
		 <description><![CDATA[RESEARCH TRIANGLE PARK, N.C., Feb. 4  (HSMN NewsFeed)  -- Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced today that Gwendolyn Powell Painter, M.D., M.P.H., has joined the company as Chief Medical Offic... <br/><font color="red">Biopharmaceuticals, Personnel</font><br/><font color="blue">Chimerix</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[American Shared Hospital Services Announces Contract to Supply a Leksell Gamma Knife Perfexion System to Methodist Hospital in San Antonio]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030038</link>
			<pubDate>Thu, 04 Feb 2010 13:33:41 GMT</pubDate>
			<author><![CDATA[American Shared Hospital Services]]></author>
		 <description><![CDATA[SAN FRANCISCO--(HSMN NewsFeed)--AMERICAN SHARED HOSPITAL SERVICES (NYSE AMEX:AMS), a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, announced today that it has entered into a contract to supply a... <br/><font color="red">Devices, Oncology, Neurosurgery</font><br/><font color="blue">Elekta, American Shared Hospital Services, Leksell Gamma Knife, Perfexion</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Toshiba Receives FDA Clearance for Viamo Ultrasound System]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030037</link>
			<pubDate>Thu, 04 Feb 2010 13:28:13 GMT</pubDate>
			<author><![CDATA[Toshiba America Medical Systems]]></author>
		 <description><![CDATA[New Portable Laptop System Offers Best-In-Class Imaging Capabilities in a Laptop Size

TUSTIN, Calif.--(HSMN NewsFeed)--Designed to meet the needs of today’s hospitals by combining portability with high-end radiology features, Toshiba America Medical Sys... <br/><font color="red">Devices, Radiology</font><br/><font color="blue">Toshiba America Medical Systems, Viamo, laptop ultrasound</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Launch of Ipsen's Decapeptyl(R) 6-Month Formulation (LP 22.5 mg) in France for the Treatment of Locally Advanced or Metastatic Hormone-Dependent Prostate Cancer]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030036</link>
			<pubDate>Thu, 04 Feb 2010 13:22:55 GMT</pubDate>
			<author><![CDATA[Ipsen]]></author>
		 <description><![CDATA[Paris & LAUSANNE, Switzerland, Feb 4 --(HSMN NewsFeed)--Ipsen (Paris:IPN ), an innovation-driven global specialty pharmaceutical group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the developm... <br/><font color="red">Biopharmaceuticals, Oncology</font><br/><font color="blue">Ipsen, Debiopharm, Decapeptyl, triptorelin embonate, prostate cancer</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Cardiac Science Notifies AED Customers of Voluntary Medical Device Recall]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030035</link>
			<pubDate>Wed, 03 Feb 2010 22:02:36 GMT</pubDate>
			<author><![CDATA[Cardiac Science]]></author>
		 <description><![CDATA[BOTHELL, Wash., Feb. 3  (HSMN NewsFeed)  -- Cardiac Science Corporation (Nasdaq: CSCX) is initiating a worldwide voluntary recall after determining that approximately 12,200 automated external defibrillators (AEDs) may not be able to deliver therapy during... <br/><font color="red">Devices, Product Recall</font><br/><font color="blue">Cardiac Science, automated external defibrillators, Powerheart, CardioVive</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Poniard Pharmaceuticals Announces Management Changes and Reduction in Force]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030033</link>
			<pubDate>Wed, 03 Feb 2010 19:49:13 GMT</pubDate>
			<author><![CDATA[Poniard Pharmaceuticals]]></author>
		 <description><![CDATA[Ronald A. Martell Named Chief Executive Officer

Michael S. Perry, DVM, Ph.D., Named President and Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., Feb. 3  (HSMN NewsFeed)  -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company... <br/><font color="red">Biopharmaceuticals, Personnel</font><br/><font color="blue">Poniard Pharmaceuticals</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Noven Appoints Patrick Gallagher as Vice President]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030032</link>
			<pubDate>Wed, 03 Feb 2010 19:43:29 GMT</pubDate>
			<author><![CDATA[Noven Pharmaceuticals]]></author>
		 <description><![CDATA[MIAMI--(HSMN NewsFeed)--Noven Pharmaceuticals, Inc. today announced the appointment of Patrick Gallagher as the company’s new Vice President of Business Development. In this role, Gallagher will be responsible for all business development activities at Nov... <br/><font color="red">Biopharmaceuticals, Personnel</font><br/><font color="blue">Noven Pharmaceuticals</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Penrose-St. Francis Health Systems adopts TandemHeart(R) - versatile circulatory support device from CardiacAssist]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030031</link>
			<pubDate>Wed, 03 Feb 2010 17:21:28 GMT</pubDate>
			<author><![CDATA[CardiacAssist]]></author>
		 <description><![CDATA[COLORADO SPRINGS, Colo. & PITTSBURGH--(HSMN NewsFeed)--CardiacAssist Inc. announced today that Penrose-St. Francis Health Systems, Colorado Springs, Colo., has adopted the company’s TandemHeart&reg; System.

Penrose-St. Francis Health Systems is in selec... <br/><font color="red">Devices, Cardiology</font><br/><font color="blue">CardiacAssist, TandemHeart, extracorporeal circulatory support</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Viroblock SA Hires Dr. Jamie Paterson as CEO and Closes Financing Round]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030030</link>
			<pubDate>Wed, 03 Feb 2010 17:13:03 GMT</pubDate>
			<author><![CDATA[Viroblock]]></author>
		 <description><![CDATA[GENEVA, February 3  (HSMN NewsFeed)  -- Viroblock SA, a start-up dedicated to developing and commercializing a new generation of anti-viral products, today announced that Dr. Jamie Paterson will join Viroblock as Chief Executive Officer (CEO).

Jamie Pat... <br/><font color="red">Biopharmaceuticals, Personnel, Venture Capital</font><br/><font color="blue">Viroblock</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Scott Canute Joins Genzyme to Head Manufacturing and Corporate Operations]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030029</link>
			<pubDate>Wed, 03 Feb 2010 17:09:09 GMT</pubDate>
			<author><![CDATA[Genzyme]]></author>
		 <description><![CDATA[Eli Lilly Veteran Brings Record of Manufacturing Transformation, Excellence

CAMBRIDGE, Mass.--(HSMN NewsFeed)--Genzyme Corporation (NASDAQ: GENZ ) announced today that Scott Canute, the former manufacturing head at Eli Lilly & Company and a respected le... <br/><font color="red">Biopharmaceuticals, Personnel</font><br/><font color="blue">Genzyme</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[PSS World Medical Appoints Gary A. Corless as President and Chief Executive Officer]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030028</link>
			<pubDate>Wed, 03 Feb 2010 15:23:06 GMT</pubDate>
			<author><![CDATA[PSS World Medical]]></author>
		 <description><![CDATA[CEO David A. Smith Steps Down as Chairman and CEO

Delores P. Kesler Named Chairman of the Board

JACKSONVILLE, Fla., Feb. 3  (HSMN NewsFeed)  -- PSS World Medical, Inc. (Nasdaq: PSSI) today announced that its Board of Directors has unanimously appoint... <br/><font color="red">Devices, Personnel</font><br/><font color="blue">PSS World Medical</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Speedus Engages Morgan Joseph to Evaluate Strategic Alternatives for Zargis Subsidiary]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030027</link>
			<pubDate>Wed, 03 Feb 2010 15:18:48 GMT</pubDate>
			<author><![CDATA[Speedus]]></author>
		 <description><![CDATA[FREEHOLD, N.J., Feb. 3  (HSMN NewsFeed)  -- Speedus Corp. (Nasdaq: SPDE), announced today that it has engaged Morgan Joseph & Co. Inc., a full service investment bank, to evaluate strategic alternatives available to maximize shareholder value with respect ... <br/><font color="red">Devices, Cardiology</font><br/><font color="blue">Zargis Medical, Speedus, Cardioscan</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[NxStage(R) and Nordic Medcom Sign Distribution Agreement for the System One(TM)]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030026</link>
			<pubDate>Wed, 03 Feb 2010 15:14:43 GMT</pubDate>
			<author><![CDATA[NxStage Medical]]></author>
		 <description><![CDATA[NxStage's portable home hemodialysis system to be available in Sweden, Denmark and Finland

LAWRENCE, Mass., Feb. 3  (HSMN NewsFeed)  -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that it... <br/><font color="red">Devices, Distribution</font><br/><font color="blue">NxStage Medical, Nordic Medcom, NxStage System One, hemodialysis</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Cymbalta(R) Significantly Reduced Chronic Low Back Pain in New Study]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030025</link>
			<pubDate>Wed, 03 Feb 2010 15:12:19 GMT</pubDate>
			<author><![CDATA[Eli Lilly]]></author>
		 <description><![CDATA[INDIANAPOLIS, Feb. 3  (HSMN NewsFeed)  -- In a new study, 60 mg of Cymbalta&reg; (duloxetine HCl) taken once daily significantly reduced chronic low back pain, as measured by the Brief Pain Inventory (BPI) average pain rating, compared with placebo.(1) The... <br/><font color="red">Biopharmaceuticals</font><br/><font color="blue">Eli Lilly, Cymbalta, duloxetine, back pain</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Medicis Receives Approval for RESTYLANE(R) and PERLANE(R) With Lidocaine]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030024</link>
			<pubDate>Wed, 03 Feb 2010 15:09:32 GMT</pubDate>
			<author><![CDATA[Medicis Pharmaceutical]]></author>
		 <description><![CDATA[SCOTTSDALE, Ariz., Feb. 3, 2010 --(HSMN NewsFeed) -- Medicis (NYSE:MRX ) today announced that the U.S. Food and Drug Administration (FDA) has approved the dermal fillers RESTYLANE&reg;-L and PERLANE&reg;-L.  RESTYLANE-L is approved for implantation into th... <br/><font color="red">Devices, Dermatology, FDA</font><br/><font color="blue">Medicis Pharmaceutical, RESTYLANE, PERLANE, hyaluronic acid, dermal filler</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Linden Acquires Hycor Biomedical Business from Agilent Technologies]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030023</link>
			<pubDate>Wed, 03 Feb 2010 15:03:37 GMT</pubDate>
			<author><![CDATA[Agilent Technologies]]></author>
		 <description><![CDATA[CHICAGO & SANTA CLARA, Calif.--(HSMN NewsFeed)--Linden LLC, a Chicago-based healthcare private equity firm, today announced it has acquired Hycor Biomedical Inc. from Agilent Technologies (NYSE:A ). Hycor develops, manufactures and markets in vitro diagnos... <br/><font color="red">Diagnostics, Acquisitions</font><br/><font color="blue">Agilent Technologies, Hycor Biomedical, Linden LLC</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[St. Jude Medical Announces IRASE AF Clinical Trial to Evaluate Cardiac Ablation Catheter System for Treatment of Atrial Fibrillation]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030022</link>
			<pubDate>Wed, 03 Feb 2010 15:00:27 GMT</pubDate>
			<author><![CDATA[St. Jude Medical]]></author>
		 <description><![CDATA[IRASE AF is the company’s first clinical trial seeking atrial fibrillation indication utilizing unique Duo tip irrigation technology for an RF ablation catheter

ST. PAUL, Minn.--(HSMN NewsFeed)--St. Jude Medical, Inc. (NYSE:STJ ) today announced it has ... <br/><font color="red">Devices, Cardiology</font><br/><font color="blue">St. Jude Medical, tip irrigated ablation catheter, atrial fibrillation</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Sanomedics Names Jordan Serlin Chief Operating Officer]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030021</link>
			<pubDate>Wed, 03 Feb 2010 14:55:42 GMT</pubDate>
			<author><![CDATA[Sanomedics]]></author>
		 <description><![CDATA[Previous Public Company Operating Experience Seen as a Major Benefit

MIAMI--(HSMN NewsFeed)--Sanomedics International Holdings, Inc. (Pink Sheets: SIMH ) announced the appointment of Jordan Serlin as Chief Operating Officer for the company. Additionally... <br/><font color="red">Devices, Personnel</font><br/><font color="blue">Sanomedics</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Acorda Therapeutics Announces Pricing and Patient Assistance Programs for AMPYRA (dalfampridine)]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030020</link>
			<pubDate>Wed, 03 Feb 2010 13:33:09 GMT</pubDate>
			<author><![CDATA[Acorda Therapeutics]]></author>
		 <description><![CDATA[AMPYRA Wholesale Acquisition Price Set at $1,056 per 30-Day Supply

Patient Assistance Program Launched for Uninsured and Underinsured To Provide AMPYRA at No Cost

Co-Pay Program Implemented To Help Manage Out-of-Pocket Expenses

HAWTHORNE, N.Y.--(H... <br/><font color="red">Biopharmaceuticals, Neurology</font><br/><font color="blue">Acorda Therapeutics, AMPYRA, dalfampridine, multiple sclerosis</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Silodosin (Urorec(R)/Silodyx) Approved by the European Commission for the Treatment of the Signs and Symptoms of BPH (Benign Prostatic Hyperplasia)]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030019</link>
			<pubDate>Wed, 03 Feb 2010 13:26:42 GMT</pubDate>
			<author><![CDATA[RECORDATI]]></author>
		 <description><![CDATA[MILAN, ITALY, Feb 3, --(HSMN NewsFeed)-- Recordati announces that it has been granted Marketing Authorization by the European Commission for the medicinal products Urorec&reg; and Silodyx 4 mg, 8 mg, hard capsules, intended for treatment of the signs and s... <br/><font color="red">Biopharmaceuticals,  Urology, Regulatory</font><br/><font color="blue">RECORDATI, Urorec, Silodyx, benign prostatic hyperplasia</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Medco Acquires Leading Genetics Healthcare Company, DNA Direct]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030034</link>
			<pubDate>Wed, 03 Feb 2010 04:00:00 GMT</pubDate>
			<author><![CDATA[Medco Health Solutions]]></author>
		 <description><![CDATA[Combined capabilities will deliver precision health services designed to improve clinical and financial outcomes

FRANKLIN LAKES, N.J. and SAN FRANCISCO, Feb. 2  (HSMN NewsFeed)  -- Committed to being at the forefront of translating personalized medicine... <br/><font color="red">Diagnostics, Personalized Medicine, Mergers & Acquisitions</font><br/><font color="blue">Medco Health Solutions, DNA Direct, genomic medicine</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Auxilium Announces U.S. Food and Drug Administration Approval for XIAFLEX(TM) for the Treatment of Dupuytren's Contracture]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030018</link>
			<pubDate>Wed, 03 Feb 2010 02:46:21 GMT</pubDate>
			<author><![CDATA[Auxilium Pharmaceuticals]]></author>
		 <description><![CDATA[Auxilium to Host Conference Call and Webcast on Wednesday, February 3 at 8:30 a.m. Eastern Time

MALVERN, PA, Feb 2 --(HSMN NewsFeed) - Auxilium Pharmaceuticals, Inc. (NASDAQ:AUXL ), a specialty biopharmaceutical company, today announced that it has rece... <br/><font color="red">Biopharmaceuticals, FDA</font><br/><font color="blue">Auxilium Pharmaceuticals, XIAFLEX, Dupuytren's contracture</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Sensors for Medicine and Science, Inc. Names Dr. Paul Strumph as Chief Medical Officer]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030017</link>
			<pubDate>Tue, 02 Feb 2010 19:45:22 GMT</pubDate>
			<author><![CDATA[Sensors for Medicine and Science]]></author>
		 <description><![CDATA[GERMANTOWN, Md., Feb. 2  (HSMN NewsFeed)  -- Sensors for Medicine and Science, Inc., a clinical-stage, medical device company pioneering breakthrough technology that could dramatically improve glucose monitoring for people with diabetes, today announced th... <br/><font color="red">Devices, Monitoring, Endocrinology, Personnel</font><br/><font color="blue">Sensors for Medicine and Science, implanted continuous glucose monitor</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Two Studies Find Artefill(R) to Be a Long-Term Treatment Option for Facial Lipoatrophy]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030016</link>
			<pubDate>Tue, 02 Feb 2010 19:32:51 GMT</pubDate>
			<author><![CDATA[Suneva Medical]]></author>
		 <description><![CDATA[Investigator-Initiated Studies Examine Artefill's Use with Age-Related and HIV-Associated Facial Lipoatrophy Patients

SAN DIEGO, Feb. 2  (HSMN NewsFeed)  -- Suneva Medical, a privately-held aesthetic medical device company, today announced that two clin... <br/><font color="red">Devices, Dermatology</font><br/><font color="blue">Suneva Medical, Artefill, lipoatrophy</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Bio-Matrix Scientific Group's Majority Owned Subsidiary Entest BioMedical Initiates Studies to Support Stem Cell / Laser Regenerative Therapy for COPD]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030015</link>
			<pubDate>Tue, 02 Feb 2010 16:29:07 GMT</pubDate>
			<author><![CDATA[Bio-Matrix Scientific Group]]></author>
		 <description><![CDATA[Every 4 Minutes an American Dies of COPD

24 Million Americans Have COPD and 12 Million Don't Know It

$170 Billion over the Next 5 Years Will Be Spent Treating COPD

SAN DIEGO, CA - (HSMN NewsFeed) - Bio-Matrix Scientific Group Inc. (OTC.BB:BMSN ) a... <br/><font color="red">Regenerative Medicine</font><br/><font color="blue">Bio-Matrix Scientific Group, Entest BioMedical, stem cell, COPD</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Veran Medical Receives FDA Clearances to Expand Uses for ig4 Navigation System to Use Ultrasound and 3D Fluoroscopic X-ray]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030014</link>
			<pubDate>Tue, 02 Feb 2010 16:24:32 GMT</pubDate>
			<author><![CDATA[Veran Medical Technologies]]></author>
		 <description><![CDATA[ST LOUIS, Feb. 2  (HSMN NewsFeed)  -- Veran Medical Technologies announced today that it has recently received two clearances (K093146 & K093995) from the U.S. Food and Drug Administration (FDA) to expand its indications for use of the ig4 Navigation platf... <br/><font color="red">Devices, Oncology, FDA</font><br/><font color="blue">Veran Medical Technologies, ig4, electromagnetic navigation, thermal ablation</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[FDA Accepts Javelin Pharmaceuticals' Submission and Files New Drug Application for Dyloject(TM)]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030013</link>
			<pubDate>Tue, 02 Feb 2010 16:10:57 GMT</pubDate>
			<author><![CDATA[Myriad Pharmaceuticals]]></author>
		 <description><![CDATA[Key Milestone in the Proposed Merger of Myriad Pharmaceuticals and Javelin Pharmaceuticals

SALT LAKE CITY, Feb. 2, 2010 --(HSMN NewsFeed) -- Myriad Pharmaceuticals Inc. (Nasdaq:MYRX ) today announced that the U.S. Food and Drug Administration (FDA) has ... <br/><font color="red">Biopharmaceuticals, FDA, Mergers & Acquisitions</font><br/><font color="blue">Myriad Pharmaceuticals, Javelin Pharmaceuticals, Dyloject</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Addenbrooke's Hospital Begins Treating Patients on Second TomoTherapy(R) Cancer Treatment System]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030012</link>
			<pubDate>Tue, 02 Feb 2010 16:07:18 GMT</pubDate>
			<author><![CDATA[TomoTherapy]]></author>
		 <description><![CDATA[Expanded Capacity Provides Cambridge, England-Based Hospital With Ability to Treat More Patients With Advanced Image-Guided IMRT

MADISON, WI - (HSMN NewsFeed) - TomoTherapy Incorporated (NASDAQ:TOMO ), maker of advanced radiation therapy solutions for c... <br/><font color="red">Devices, Oncology</font><br/><font color="blue">TomoTherapy, Hi-Art, radiotherapy, IMRT</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Alphatec Spine Receives CE Mark for its OsseoScrew(TM) Spinal Fixation System and Its GLIF/ ARC(TM) Portal Access System]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030011</link>
			<pubDate>Tue, 02 Feb 2010 16:00:20 GMT</pubDate>
			<author><![CDATA[Alphatec Spine]]></author>
		 <description><![CDATA[EU Market Release of OsseoScrew in 1Q 2010 and GLIF in the Second Half of 2010

CARLSBAD, Calif., Feb. 2, 2010 --(HSMN NewsFeed) -- Alphatec Holdings, Inc. (Nasdaq:ATEC ), the parent company of Alphatec Spine, Inc., a medical device company that designs,... <br/><font color="red">Devices, Orthopaedic, Neurosurgery, Regulatory</font><br/><font color="blue">Alphatec Spine, OsseoScrew, Spinal Fixation, Guided Lumbar Interbody Fusion</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Guided Therapeutics, Inc. Receives New Funding Commitment from Konica Minolta Opto, Inc. to Expand Cancer Detection Product Line]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030010</link>
			<pubDate>Tue, 02 Feb 2010 15:57:38 GMT</pubDate>
			<author><![CDATA[Guided Therapeutics]]></author>
		 <description><![CDATA[NORCROSS, Ga.--(HSMN NewsFeed)--Guided Therapeutics, Inc. (GT) (Pink Sheets: GTHP ) today announced that it has received confirmation of additional funding from Konica Minolta Opto, Inc. (KMOT) of Tokyo to co-develop new, non-invasive cancer detection prod... <br/><font color="red">Devices, Diagnostics, Oncology</font><br/><font color="blue">Guided Therapeutics, LightTouch, cervical cancer</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[STAAR Surgical's Visian(R) ICL(TM) is First Phakic Lens to Be Approved in Japan]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030009</link>
			<pubDate>Tue, 02 Feb 2010 15:49:57 GMT</pubDate>
			<author><![CDATA[STAAR Surgical]]></author>
		 <description><![CDATA[MONROVIA, Calif., Feb. 2  (HSMN NewsFeed)  -- STAAR Surgical Company (Nasdaq: STAA), a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, announced today regulatory approval from the Japanese Ministry of Health, Labor a... <br/><font color="red">Devices, Ophthalmology, Regulatory</font><br/><font color="blue">STAAR Surgical, Visian, Implantable Collamer Lens, myopia</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Journal of American College of Cardiology Publishes Study Demonstrating Safety and Effectiveness of Laser Assisted Lead Removal]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030008</link>
			<pubDate>Tue, 02 Feb 2010 15:10:13 GMT</pubDate>
			<author><![CDATA[Spectranetics]]></author>
		 <description><![CDATA[Spectranetics’ LExICon Study Achieves 97.7% Clinical Success Rate in Removal Procedures

COLORADO SPRINGS, Colo.--(HSMN NewsFeed)--Spectranetics Corporation (NASDAQ: SPNC ) today announced publication of the four-year, retrospective LExICon (Lead Extract... <br/><font color="red">Devices, Cardiology</font><br/><font color="blue">Spectranetics, LExICon study, laser assisted lead removal</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Orexo Announces That Partner Kyowa Hakko Kirin Entered a Joint Distribution Agreement on KW-2246 for Treatment of Cancer Pain in Japan]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2030007</link>
			<pubDate>Tue, 02 Feb 2010 13:36:20 GMT</pubDate>
			<author><![CDATA[Orexo]]></author>
		 <description><![CDATA[UPPSALA, Sweden--(HSMN NewsFeed)--Orexo AB (STO:ORX) announces today that its partner Kyowa Hakko Kirin Co., Ltd. has entered a joint distribution agreement for the cancer pain drug KW-2246 (Orexo’s sublingual fentanyl product) with the pharmaceutical comp... <br/><font color="red">Biopharmaceuticals, Distribution</font><br/><font color="blue">Orexo, Kyowa Hakko Kirin, Hisamitsu Pharmaceutical, Abstral</font>]]>
			</description>
	</item>
	</channel>
</rss>